China Biologic Products (NASDAQ: CBPO) is one of 282 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare China Biologic Products to related businesses based on the strength of its valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.
This table compares China Biologic Products and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|China Biologic Products||31.29%||21.49%||18.58%|
|China Biologic Products Competitors||-5,335.76%||-435.50%||-40.48%|
This is a summary of recent ratings and price targets for China Biologic Products and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|China Biologic Products||0||1||2||0||2.67|
|China Biologic Products Competitors||808||3169||11491||230||2.71|
China Biologic Products currently has a consensus price target of $137.50, indicating a potential upside of 61.59%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.75%. Given China Biologic Products’ higher possible upside, analysts plainly believe China Biologic Products is more favorable than its competitors.
Volatility & Risk
China Biologic Products has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, China Biologic Products’ competitors have a beta of 0.99, suggesting that their average stock price is 1% less volatile than the S&P 500.
Insider and Institutional Ownership
71.1% of China Biologic Products shares are owned by institutional investors. Comparatively, 49.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 2.7% of China Biologic Products shares are owned by company insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares China Biologic Products and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|China Biologic Products||$341.17 million||$104.77 million||21.43|
|China Biologic Products Competitors||$286.20 million||$34.74 million||146.58|
China Biologic Products has higher revenue and earnings than its competitors. China Biologic Products is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
China Biologic Products beats its competitors on 8 of the 13 factors compared.
About China Biologic Products
China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
What are top analysts saying about China Biologic Products Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for China Biologic Products Inc. and related companies.